secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001193125-24-241397
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

RMC-6236 shows 8.5-month median PFS in 2L metastatic PDAC
---------------------------------------------------------

- Median PFS of 8.5 months (95% CI: 5.3-11.7) in 2L PDAC with KRAS G12X; 4.4 months in 3L+.
- Median OS of 14.5 months in 2L PDAC; 6-month OS rate 89% (KRAS G12X) and 91% (broader RAS mutant).
- ORR 29% (2L) and 22% (3L+); disease control rate 91% (2L) and 89% (3L+).
- Safety: 98% any grade TRAEs, 29% Grade≥3; no discontinuations; mean dose intensity 92%.
- Data cutoff July 23, 2024; 127 PDAC patients across 160-300 mg daily doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524241397/0001193125-24-241397-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000119312524241397/d750511d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-241397

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer